1
|
Golubev SA, Lezheiko TV, Korovaitseva GI, Gabaeva MV, Kolesina NY, Kaleda VG, Golimbet VE. [Prognosis of the functional outcome of schizophrenia using a multigene panel]. Zh Nevrol Psikhiatr Im S S Korsakova 2021; 121:70-76. [PMID: 34460160 DOI: 10.17116/jnevro202112107170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE To compare the groups of schizophrenic patients with different levels of functional outcome and different frequency of risk variants in polymorphic loci of five candidate genes to create a multigene panel and to test its predictive ability for long-term outcome of the disease. MATERIAL AND METHODS According to the proposed typology, the patients included in the studies were divided into three groups, which differed in the level of social functioning. Group 1 was characterized by the highest level, in group 2 this indicator was significantly lower, and in group 3 the lowest. The multigenic panel included genes for serotonin receptor type 2a (5-HTR2A T102C), serotonin transporter (5-HTTLPR), C-reactive protein (CRP -717A>G), angiotensin II receptor type 1 (AGTR1 A1166C), and brain neurotrophic factor (BDNF Val66Met). A multi-gene risk score was calculated for each patient by summing the total number all his/her risk alleles. For each polymorphism, a score of 2 was assigned to homozygous high-risk genotypes, a score of 1 to heterozygous genotypes and a score of 0 to homozygous low-risk genotype. Accordingly, the multi-gene risk score for a patient could vary from 0 to 10 risk alleles. RESULTS A significant effect of the group on the multi-gene risk score was shown (p<0.0001). Between-group differences were significant as well (p<0.01). In group 1, there were no carriers of ≥6 risk alleles, and the number of carriers of less than 5 alleles exceeded 50%. In group 2, the number of carriers of ≥6 risk alleles was 19.4%, and in group 3 - 31.7%. Moreover, in these groups there were no carriers of 0-2 risk alleles, while in group 1 their number was 20.7%. CONCLUSION The multi-gene risk score predicts the level of functional outcome in patients with schizophrenia. In the case of a smaller number of risk alleles (0-4) in an individual, a favorable functional outcome can be predicted with a high probability in the long-term period of the disease.
Collapse
Affiliation(s)
- S A Golubev
- Mental Health Research Centre, Moscow, Russia.,Gannushkin Psychiatric Clinical Hospital No. 4, Moscow, Russia
| | | | | | - M V Gabaeva
- Mental Health Research Centre, Moscow, Russia
| | | | - V G Kaleda
- Mental Health Research Centre, Moscow, Russia
| | - V E Golimbet
- Mental Health Research Centre, Moscow, Russia.,Alexeev Moscow Psychiatric Hospital No. 1, Moscow, Russia
| |
Collapse
|
2
|
Alfimova MV, Lezheiko TV, Smirnova SV, Gabaeva MV, Golimbet VV. Effect of the C-reactive protein gene on risk and clinical characteristics of schizophrenia in winter-born individuals. Eur Neuropsychopharmacol 2020; 35:81-88. [PMID: 32402651 DOI: 10.1016/j.euroneuro.2020.03.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 03/16/2020] [Accepted: 03/27/2020] [Indexed: 12/16/2022]
Abstract
C-reactive protein (CRP) levels are elevated in a subset of schizophrenia patients and correlated with more severe symptoms, which makes CRP a potential theranostic biomarker for the disease. However, genotypes associated with higher CRP concentrations have the protective effect against schizophrenia. To resolve this discrepancy, more research on the role of CRP in schizophrenia is needed. The present study aimed to investigate the effects on schizophrenia of the CRP gene in combination with season of birth (SOB), the known risk factor for the disease. We first examined the impact of seasonality on schizophrenia risk in the Russian population, using samples of 2452 patients and 1203 controls, and then assessed the CRP rs2794521 polymorphism × SOB interaction effect on the disease risk, age-of-onset and symptoms severity in 826 patients and 476 controls. An excess of winter births in patients was not significant. At the same time, we found that winter-born patients carrying the CRP GG genotype, which is associated with low transcriptional activity, had an earlier age at onset than the other patients. The findings are in line with the protective role of high active CRP genetic variants in the development of schizophrenia and provide support for the hypothesis that this effect of CRP takes place early in life.
Collapse
Affiliation(s)
- Margarita V Alfimova
- Department of Clinical Genetics, Mental Health Research Center, 34 Kashirskoe shosse, 115522 Moscow, Russian Federation.
| | - Tatyana V Lezheiko
- Department of Clinical Genetics, Mental Health Research Center, 34 Kashirskoe shosse, 115522 Moscow, Russian Federation
| | - Svetlana V Smirnova
- Department of Clinical Genetics, Mental Health Research Center, 34 Kashirskoe shosse, 115522 Moscow, Russian Federation
| | - Marina V Gabaeva
- Department of Clinical Genetics, Mental Health Research Center, 34 Kashirskoe shosse, 115522 Moscow, Russian Federation
| | - Vera V Golimbet
- Department of Clinical Genetics, Mental Health Research Center, 34 Kashirskoe shosse, 115522 Moscow, Russian Federation
| |
Collapse
|
3
|
Fedorenko OY, Golimbet VE, Ivanova SА, Levchenko А, Gainetdinov RR, Semke AV, Simutkin GG, Gareeva АE, Glotov АS, Gryaznova A, Iourov IY, Krupitsky EM, Lebedev IN, Mazo GE, Kaleda VG, Abramova LI, Oleichik IV, Nasykhova YA, Nasyrova RF, Nikolishin AE, Kasyanov ED, Rukavishnikov GV, Timerbulatov IF, Brodyansky VM, Vorsanova SG, Yurov YB, Zhilyaeva TV, Sergeeva AV, Blokhina EA, Zvartau EE, Blagonravova AS, Aftanas LI, Bokhan NА, Kekelidze ZI, Klimenko TV, Anokhina IP, Khusnutdinova EK, Klyushnik TP, Neznanov NG, Stepanov VA, Schulze TG, Kibitov АО. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Mol Psychiatry 2019; 24:1099-1111. [PMID: 30664668 PMCID: PMC6756082 DOI: 10.1038/s41380-019-0354-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 12/27/2018] [Accepted: 12/31/2018] [Indexed: 12/18/2022]
Abstract
We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.
Collapse
Affiliation(s)
- Olga Yu Fedorenko
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
- National Research Tomsk Polytechnic University, Tomsk, Russian Federation.
| | | | - Svetlana А Ivanova
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk Polytechnic University, Tomsk, Russian Federation
| | - Аnastasia Levchenko
- Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Raul R Gainetdinov
- Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Arkady V Semke
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - German G Simutkin
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - Аnna E Gareeva
- Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | - Аndrey S Glotov
- Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Anna Gryaznova
- Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany
| | - Ivan Y Iourov
- Mental Health Research Center, Moscow, Russian Federation
| | - Evgeny M Krupitsky
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Igor N Lebedev
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
| | - Galina E Mazo
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | | | | | | | - Yulia A Nasykhova
- Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Regina F Nasyrova
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Anton E Nikolishin
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Evgeny D Kasyanov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Grigory V Rukavishnikov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Ilgiz F Timerbulatov
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | - Vadim M Brodyansky
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Svetlana G Vorsanova
- Veltischev Research and Clinical Institute for Pediatrics, the Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | - Yury B Yurov
- Mental Health Research Center, Moscow, Russian Federation
| | - Tatyana V Zhilyaeva
- Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation
| | | | - Elena A Blokhina
- First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation
| | - Edwin E Zvartau
- First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation
| | - Anna S Blagonravova
- Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation
| | - Lyubomir I Aftanas
- Federal State Scientific Budgetary Institution "Scientific Research Institute of Physiology and Basic Medicine,", Novosibirsk, Russian Federation
| | - Nikolay А Bokhan
- Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk State University, Tomsk, Russian Federation
| | - Zurab I Kekelidze
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Tatyana V Klimenko
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Irina P Anokhina
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| | - Elza K Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation
- Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation
| | | | - Nikolay G Neznanov
- V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation
| | - Vadim A Stepanov
- Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation
- National Research Tomsk State University, Tomsk, Russian Federation
| | - Thomas G Schulze
- Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany
| | - Аleksandr О Kibitov
- Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
| |
Collapse
|
4
|
Golimbet VE, Kaleda VG, Korovaitseva GI, Lezheiko TV, Kasparov SV, Krikova EV, Tikhonov DV. [Genetic variations associated with premorbid personality in patients with schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119:55-59. [PMID: 31089096 DOI: 10.17116/jnevro201911903155] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
AIM To search for genetic variants associated with premorbid personality in patients with schizophrenia. MATERIAL AND METHODS The sample included 272 men diagnosed with schizophrenia or schizoaffective disorder. Patients were divided into 3 groups based on premorbid personality difficulties: mild (group 1, n=110), moderate (group 2, n=113), marked (group 3, n=49). The following polymorphisms were genotyped: 5-HTR2A (T102C), 5-HTTLPR, BDNF (Val66Met), CRP (-717A>G). RESULTS A significant increase in the frequency of the CC (5-HTR2A T102C), LL (5-HTTLPR) and Met/Met (BDNF Val66Met) genotypes was identified in group 3 compared to group 1. Frequencies of CC and LL genotypes were significantly higher in group 2 compared to group 1 as well. The differences between group 2 and group 3 were found only for the Met/Met genotype. There were no between-group differences in the frequencies of CRP (-717A>G) genotypes. CONCLUSION 5-HTR2A (T102C), 5-HTTLPR, BDNF (Val66Met) polymorphisms previously reported to modify schizophrenia course are also associated with premorbid personality in schizophrenic patients.
Collapse
Affiliation(s)
| | - V G Kaleda
- Mental Health Research Center, Moscow, Russia
| | | | | | | | - E V Krikova
- Mental Health Research Center, Moscow, Russia
| | | |
Collapse
|